No Data
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
